Bull case
Oculis Holding is attractive fundamentally because licaminlimab (OCS-02) has already produced encouraging Phase 2 DED results, including statistically significant symptom relief in 134 patients and a biomarker-enriched objective sign signal in RELIEF, with favorable tolerability and no treatment-related serious ocular safety signal. The investment case is further strengthened by PREDICT-1, an actively enrolling ~160-patient precision-medicine study targeting the TNFR1 genotype, which could validate a differentiated, genotype-guided DED approach and support meaningful commercial potential with peak annual sales modeled at $1.7B and 55% probability of success. In parallel, privosegtor (OCS-05) has FDA Breakthrough Therapy designation and SPA alignment for optic neuritis, a rare sight-threatening condition with no approved neuroprotective treatments and a potential $7B U.S. market, while the company’s ~$278MM cash position funds operations into 2H29.